Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
36 hedge funds and large institutions have $13.9M invested in Paratek Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 5 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
8% more capital invested
Capital invested by funds: $12.8M → $13.9M (+$1.05M)
0% more funds holding
Funds holding: 36 → 36 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$668K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$282K |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$218K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$178K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$417K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$223K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$152K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$108K |
| 5 |
D.E. Shaw & Co
New York
|
-$96.4K |
PRTK Hedge Fund Activity: Q3 2014 in Review
36 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2014, worth a combined $13.9M — up 8.2% from $12.8M a quarter earlier.
Fund positioning in PRTK was balanced in Q3 2014: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 8 trimmed.
The largest buyer was Roumell Asset Management, adding an estimated $668K. The largest seller was AQR Capital Management, exiting entirely with an estimated $417K sold.
- 36 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $13.9M of Paratek Pharmaceuticals, Inc. stock for Q3 2014, up 8.2% quarter-over-quarter.
- 5 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2014 and 5 closed out, a net change of 0 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2014 was Roumell Asset Management, an estimated $668K added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2014 was AQR Capital Management, an estimated $417K sold.
Based on aggregated 13F filings for Q3 2014.